

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6A

(Whole IgG)	HPLC 2-AB Labeled Glycan Analysis				
	Area %	G0	G0F	G1F	G2F
ERBITUX KGaA		1.6	51.1	39.5	7.8
HLX05		2.5	61.2	32.4	3.8
1-26/2-68		1.8	73.9	22.6	1.7
1-26/3-67		3.2	78.4	17.2	1.2
8/33		2.0	70.2	25.8	2.0
34/33		1.3	56.0	37.4	5.3

Fig. 6B

(130619) Conclusion of Glycan on Fab/Fc
(Separate Fab & Fc)

Sample	Fragment	Glycan Profile	
Erbitux (Merk) KGaA	Fc	G0F G1F G2F (trace)	G0F
	Fab	G2F+2*Gal G2F+Gal+SA(NeuGc)	G1F G2F
HLX05	Fc	G0F G1F G2F (trace)	G2F+2*Gal
	Fab	G2F G2F+SA(NeuAc) G2F+2*SA(NeuAc)	G2F+Gal+SA(NeuGc)
	Fc	G0F G1F	G2F+SA(NeuAc)
1-26/3-67	Fab	---	G2F+2*SA(NeuAc)



Fig. 7




Fig. 8




Fig. 8G

(ng/ml)	ADCC (PBMC 400K/well)		ADCC (PBMC 600K/well)	
	Avg EC50	% of Activity	Avg EC50	% of Activity
HLX05	99.7	100	80.6	100
1-26/2-68	118.7	84	84.7	95
1-26/3-67	110.2	90	74.2	109
8/33	91.4	109	87.0	93
34/33	80.3	124	72.9	111

Fig. 9




Fig. 9D

Fig. 9E

Fig. 9F

Fig. 9A

Fig. 9B

Fig. 9C

Fig. 9G

	MTT	
	Avg IC50	% of Activity
(ng/ml)		
HLX05	285.9	100
1-26/2-68	254.5	112
1-26/3-67	220.2	130
8/33	217.2	132
34/33	236.2	121

Fig. 10




Fig. 11




Fig. 12




Fig. 13




Fig. 14A




Fig. 14B




Fig. 14C






Fig. 15A



Antibody	HLX07	HLX07-FF
EC ₅₀ (ng/ml)	4.388	1.69


Fig. 15B



Antibody	HLX07	HLX07-FF
EC ₅₀ (ng/ml)	4.663	0.968

Fig. 15C

ADCC Assay
PBMC: HT29 (BRAF^{V600E})=30:1



Antibody	HLX07	HLX07-FF
EC ₅₀ (ng/ml)	7.508	1.591

Fig. 16A




Fig. 16B




Fig. 17

